瑞舒伐他汀联合依折麦布在老年NST-ACS患者疗效和安全性观察

Evaluate the Efficacy and Safety by Using Crestor Combined with Ezetimibe in Elderly NST-ACS Patients

目的:分析瑞舒伐他汀联合依折麦布治疗NST-ACS老年患者的疗效和安全性。方法:将78例NST-ACS老年患者随机分为联合组40例和常规组38例,两组患者住院当天即给予瑞舒伐他汀10mg/d,联合组在常规治疗基础上加用依折麦布,观察两组疗效和安全性。结果:两组第7、30天TC和LDL-C水平与治疗前相比均有明显下降,而联合组降低更加显著(P<0.05)。两组在治疗过程中均未发现肝酶升高、肌酶升高等不良反应,未出现因不良反应而停药的病例。结论:常规剂量瑞舒伐他汀联合依折麦布治疗NST-ACS,其治疗安全性和耐受性良好。

Objective： To analyze the safety and efficacy by using crestor combined with ezetimibe in elderly NST-ACS patients.Method： A total of 78 cases of NST-ACS were randomly divided into the combined group with 40 cases and the normal group with 38 cases.Two groups received Crestor 10 mg/d on the hospitalization day.The combined group received the Ezetimibe treatment on the basis of the routine treatment.Then the efficacy and safety of two groups were observed.Result： On the seventh and thirtieth day, TC and LDL-C levels were significantly decreased compared with before the treatment, and the combined group decreased more significantly （ P〈0.05 ） .Two groups during treatment were not found adverse reaction like the elevated liver enzymes, the elevated muscle enzyme and so on.There were no cases of drug discontinuation due to adverse reactions. Conclusion： The conventional dose of Crestor combined with Ezetimibe treats NST-ACS patients, the treatment is safe and well tolerated.